Second-generation interferons for cancer: clinical targets.
IFNs were the first new therapeutic products resulting from recombinant DNA technology. IFNs were also the first human proteins effective in cancer treatment. There is however much to be discovered which will lead to new clinical applications. Areas which represent major research challenges for full understanding and application of the IFN system are: (i) the diversity of the IFN family; (ii) the role of induction; (iii) molecular mechanism of action; (iv) cellular modulatory effects; (v) advantages of combinations, and (vi) identification of new therapeutic indications. This review will emphasize the diversity of the IFN family and chemical modifications which will result in second-generation IFNs. Pre-clinical and clinical findings form the basis for new therapeutic directions in chronic myelogenous leukemia, lymphomas, myelomas, melanoma, urologic malignancies, primary brain tumors, and ovarian carcinoma.
Taussig Cancer Center, Learner Research Institute, Cleveland, OH 44195, USA. bordene@cc.ccf.org
E C
EC
Borden
D
D
Lindner
R
R
Dreicer
M
M
Hussein
D
D
Peereboom
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology*; D009369:Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D007371:Interferon-gamma